Trials / Completed
CompletedNCT02039674
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pembrolizumab | IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy |
| DRUG | Paclitaxel | IV on Day 1 of each 3-week cycle for a maximum of 4 administrations |
| DRUG | Carboplatin | IV on Day 1 of each 3-week cycle for a maximum of 4 administrations |
| BIOLOGICAL | Bevacizumab | IV on Day 1 of each 3-week cycle |
| DRUG | Pemetrexed | IV on Day 1 of each 3-week cycle |
| BIOLOGICAL | Ipilimumab | IV on Day 1 of each 3-week cycle for a maximum of 4 administrations |
| DRUG | Erlotinib | Orally tablet once daily |
| DRUG | Gefitinib | Oral tablet once daily |
Timeline
- Start date
- 2014-02-21
- Primary completion
- 2016-11-07
- Completion
- 2021-10-18
- First posted
- 2014-01-17
- Last updated
- 2022-11-08
- Results posted
- 2017-12-02
Source: ClinicalTrials.gov record NCT02039674. Inclusion in this directory is not an endorsement.